PT830377E - Péptido-2 análogo ao glucagon e sua utilização terapêutica - Google Patents

Péptido-2 análogo ao glucagon e sua utilização terapêutica Download PDF

Info

Publication number: PT830377E
Authority: PT; Portugal
Prior art keywords: glucagon; peptide; therapeutic use; bowel; analogs
Prior art date: 1995-04-14

Application number

PT96908973T

Other languages

English (en)

Inventor

Daniel J Drucker

Original Assignee

Ontario Inc 1149336

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-14

Filing date

1996-04-12

Publication date

2010-01-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23675346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT830377(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-12 Application filed by Ontario Inc 1149336 filed Critical Ontario Inc 1149336

2010-01-19 Publication of PT830377E publication Critical patent/PT830377E/pt

Links

101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 3
102100040918 Pro-glucagon Human genes 0.000 title abstract 3
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 3
230000001225 therapeutic effect Effects 0.000 title abstract 2
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
230000002496 gastric effect Effects 0.000 abstract 1
230000014509 gene expression Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
230000012010 growth Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
210000004153 islets of langerhan Anatomy 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000008467 tissue growth Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Hematology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)

PT96908973T 1995-04-14 1996-04-12 Péptido-2 análogo ao glucagon e sua utilização terapêutica PT830377E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/422,540 US5990077A (en)	1995-04-14	1995-04-14	Glucagon-like peptide-2 and its therapeutic use

Publications (1)

Publication Number	Publication Date
PT830377E true PT830377E (pt)	2010-01-19

Family

ID=23675346

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT96908973T PT830377E (pt)	1995-04-14	1996-04-12	Péptido-2 análogo ao glucagon e sua utilização terapêutica

Country Status (13)

Country	Link
US (1)	US5990077A (pt)
EP (4)	EP2277530A1 (pt)
JP (3)	JPH11505521A (pt)
CN (2)	CN101254300B (pt)
AT (1)	ATE445641T1 (pt)
AU (1)	AU720493B2 (pt)
CA (1)	CA2218225C (pt)
CY (1)	CY2615B2 (pt)
DE (1)	DE69638057D1 (pt)
DK (1)	DK0830377T4 (pt)
ES (1)	ES2334864T5 (pt)
PT (1)	PT830377E (pt)
WO (1)	WO1996032414A1 (pt)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) *	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) *	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
DK1975177T3 (da)	1996-03-01	2011-07-25	Novo Nordisk As	Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
EP0906338B1 (en) *	1996-04-12	2002-11-06	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
AU753771B2 (en) *	1996-04-12	2002-10-31	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
US5994500A (en) *	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
AU4112497A (en) *	1996-08-30	1998-03-19	Novo Nordisk A/S	Glp-2 derivatives
US20020025933A1 (en) *	1996-08-30	2002-02-28	Knudsen Liselotte Bjerre	GLP-2 derivatives
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
US8592553B2 (en)	1996-12-13	2013-11-26	Nps Pharmaceuticals, Inc.	Cloned glucagon-like peptide-2 receptors
ATE358682T1 (de) *	1996-12-13	2007-04-15	Allelix Biopharma	Klonierte rezeptoren des glukagon-ähnlichen peptids-2
CA2236519C (en)	1997-05-02	2011-09-13	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
ES2210756T3 (es) *	1997-05-16	2004-07-01	1149336 Ontario Inc.	Utilizacion de agonistas del glp-2 para mejorar el funcionamiento del tracto gastrointestinal superior.
JP2002504527A (ja) *	1998-02-27	2002-02-12	ノボノルディスクアクティーゼルスカブ	部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
ATE509028T1 (de)	1999-03-15	2011-05-15	Novo Nordisk As	Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US7371721B2 (en) *	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US20080249016A1 (en) *	2000-09-18	2008-10-09	Sanos Bioscience A/S	Use of GLP-2 in a combination treatment for bone-related disorders
WO2002022151A2 (en) *	2000-09-18	2002-03-21	Osteometer Bio Tech A/S	Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20070135345A1 (en) *	2000-09-18	2007-06-14	Henriksen Dennis B	Use of GLP-2 for the treatment or prevention, of bone-related disorders
ES2311560T3 (es) *	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
ATE396202T1 (de) *	2001-02-16	2008-06-15	Conjuchem Biotechnologies Inc	Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
EP1494732B1 (en)	2002-03-20	2008-01-30	MannKind Corporation	Inhalation apparatus
US7374930B2 (en) *	2002-05-21	2008-05-20	Expression Genetics, Inc.	GLP-1 gene delivery for the treatment of type 2 diabetes
US20040038864A1 (en) *	2002-06-27	2004-02-26	Per Balschmidt	Use of dimethyl sulfone as isotonicity agent
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
WO2004035624A2 (en) *	2002-10-14	2004-04-29	Novo Nordisk A/S	Glucagon - like peptide - 2 variants
ATE502665T1 (de)	2003-02-04	2011-04-15	Novo Nordisk As	Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
BRPI0413644A (pt)	2003-08-21	2006-10-17	Novo Nordisk As	métodos para separar as duas formas de um polipeptìdeo tendo uma única racemização de aminoácido, e para separar dois polipeptìdeos, produto de polipeptìdeo, e, composição farmacêutica
ES2642214T3 (es)	2004-01-21	2017-11-15	Novo Nordisk Health Care Ag	Conjugación de péptidos mediante transglutaminasa
WO2005082404A2 (en) *	2004-02-27	2005-09-09	Novo Nordisk A/S	Glp-2 derivatives modified by lipophilic substituents
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
MX2007013431A (es) *	2005-05-04	2008-01-18	Zealand Pharma As	Analogos del peptido 2 semejante al glucagon.
CN100418983C (zh) *	2005-05-11	2008-09-17	中国药科大学	人胰高血糖素相关肽-2类似物
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
AU2007319066B2 (en)	2006-11-08	2013-09-19	Zealand Pharma A/S	Selective glucagon-like-peptide-2 (GLP-2) analogues
KR101736502B1 (ko) *	2007-10-24	2017-05-16	맨카인드 코포레이션	Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US20100081622A1 (en) *	2008-09-29	2010-04-01	Sanos Bioscience A/S	Reduction of parathyroid hormone levels
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
CN102942626B (zh) *	2009-03-05	2015-11-04	江苏豪森医药集团有限公司	胰高血糖素样肽-2类似物及其制备方法和用途
MX2011009512A (es)	2009-03-11	2011-11-29	Mannkind Corp	Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
EP2311486A1 (en) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 for use in intestine and muscle recovery
EP2314616A1 (en)	2009-10-23	2011-04-27	Ferring B.V.	Peptidic GLP-2 agonists
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
US9782454B2 (en)	2010-04-22	2017-10-10	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
EP2694402B1 (en)	2011-04-01	2017-03-22	MannKind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
EP3431098A1 (en)	2011-09-12	2019-01-23	Amunix Operating Inc.	Glucagon-like peptide-2 compositions and methods of making and using same
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
CA2865578C (en)	2012-02-27	2023-01-17	Amunix Operating Inc.	Xten conjugate compositions and methods of making same
TR201802689T4 (tr)	2012-05-03	2018-03-21	Zealand Pharma As	Glukagon benzeri peptit-2 (glp-2) analogları.
EP2872205B1 (en)	2012-07-12	2017-02-08	MannKind Corporation	Dry powder drug delivery systems
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
WO2014145718A2 (en)	2013-03-15	2014-09-18	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
CN104055757B (zh) *	2014-07-09	2016-03-16	中国人民解放军第三军医大学第三附属医院	胍丁胺用于制备治疗细菌毒素所致小肠结构损害药物的用途
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
SG10201911851VA (en)	2016-12-09	2020-02-27	Zealand Pharma As	Acylated glp-1/glp-2 dual agonists
ES2894629T3 (es)	2017-06-16	2022-02-15	Zealand Pharma As	Pautas posológicas para la administración de análogos del péptido 2 similar al glucagón (GLP-2)
BR112022006546A2 (pt)	2019-10-07	2022-08-30	Kallyope Inc	Agonistas de gpr119
CA3173731A1 (en)	2020-02-28	2021-09-02	Kallyope, Inc.	Gpr40 agonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5186117A (en)	1975-01-27	1976-07-28	Tanabe Seiyaku Co	Johoseibiryushiseizainoseiho
GB1575343A (en)	1977-05-10	1980-09-17	Ici Ltd	Method for preparing liposome compositions containing biologically active compounds
US4529561A (en)	1978-03-24	1985-07-16	The Regents Of The University Of California	Method for producing liposomes in selected size range
GB2046092B (en)	1979-03-05	1983-11-02	Toyama Chemical Co Ltd	Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en)	1982-03-22	1984-06-05	Klaus Gersonde	Method of and arrangement for producing lipid vesicles
US4725442A (en)	1983-06-17	1988-02-16	Haynes Duncan H	Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en)	1984-06-20	1991-04-16	The Liposome Company, Inc.	Extrusion technique for producing unilamellar vesicles
US4921706A (en)	1984-11-20	1990-05-01	Massachusetts Institute Of Technology	Unilamellar lipid vesicles and method for their formation
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
JP2583257B2 (ja) *	1986-05-05	1997-02-19	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン向性ホルモン
US4920016A (en)	1986-12-24	1990-04-24	Linear Technology, Inc.	Liposomes with enhanced circulation time
US5009956A (en)	1987-02-24	1991-04-23	Univ Minnesota	Phospholipase A2-resistant liposomes
US4927637A (en)	1989-01-17	1990-05-22	Liposome Technology, Inc.	Liposome extrusion method
US4944948A (en)	1989-02-24	1990-07-31	Liposome Technology, Inc.	EGF/Liposome gel composition and method
ATE164852T1 (de) *	1990-01-24	1998-04-15	Douglas I Buckley	Glp-1-analoga verwendbar in der diabetesbehandlung
SK155694A3 (en) *	1992-06-15	1995-05-10	Pfizer	Glucagon-like peptide, insulinotropin derivatives, method of their preparation, pharmaceutical agent containing and using these matters
JP2961045B2 (ja) *	1993-02-24	1999-10-12	日清製粉株式会社	腸管粘膜増強促進剤
US5990077A (en)	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
DK1975177T3 (da)	1996-03-01	2011-07-25	Novo Nordisk As	Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
EP0906338B1 (en) *	1996-04-12	2002-11-06	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs

1995
- 1995-04-14 US US08/422,540 patent/US5990077A/en not_active Expired - Lifetime
1996
- 1996-04-12 CN CN2008100012906A patent/CN101254300B/zh not_active Expired - Lifetime
- 1996-04-12 WO PCT/CA1996/000232 patent/WO1996032414A1/en not_active Ceased
- 1996-04-12 AT AT96908973T patent/ATE445641T1/de active
- 1996-04-12 JP JP8530606A patent/JPH11505521A/ja not_active Withdrawn
- 1996-04-12 EP EP10012215A patent/EP2277530A1/en not_active Withdrawn
- 1996-04-12 EP EP08154372.0A patent/EP1988100B1/en not_active Expired - Lifetime
- 1996-04-12 ES ES96908973T patent/ES2334864T5/es not_active Expired - Lifetime
- 1996-04-12 DE DE69638057T patent/DE69638057D1/de not_active Expired - Lifetime
- 1996-04-12 CA CA2218225A patent/CA2218225C/en not_active Expired - Lifetime
- 1996-04-12 EP EP96908973A patent/EP0830377B2/en not_active Expired - Lifetime
- 1996-04-12 PT PT96908973T patent/PT830377E/pt unknown
- 1996-04-12 DK DK96908973.9T patent/DK0830377T4/da active
- 1996-04-12 EP EP10012214A patent/EP2277909A1/en not_active Withdrawn
- 1996-04-12 CN CNB961946938A patent/CN100374461C/zh not_active Expired - Lifetime
- 1996-04-12 AU AU52658/96A patent/AU720493B2/en not_active Expired
2006
- 2006-07-05 JP JP2006185610A patent/JP4496183B2/ja not_active Expired - Lifetime
2010
- 2010-01-25 JP JP2010012787A patent/JP5281594B2/ja not_active Expired - Lifetime
2011
- 2011-04-15 CY CY1100004A patent/CY2615B2/xx unknown

Also Published As

Publication number	Publication date
EP0830377A1 (en)	1998-03-25
ES2334864T3 (es)	2010-03-16
EP2277530A1 (en)	2011-01-26
JP2006342172A (ja)	2006-12-21
EP0830377B1 (en)	2009-10-14
DK0830377T4 (da)	2013-03-11
JP4496183B2 (ja)	2010-07-07
DE69638057D1 (de)	2009-11-26
EP1988100A1 (en)	2008-11-05
MX9707949A (es)	1998-06-30
EP2277909A1 (en)	2011-01-26
EP1988100B1 (en)	2015-03-04
AU5265896A (en)	1996-10-30
CA2218225A1 (en)	1996-10-17
CN101254300A (zh)	2008-09-03
CY2615B2 (en)	2012-01-25
AU720493B2 (en)	2000-06-01
JP5281594B2 (ja)	2013-09-04
EP0830377B2 (en)	2012-12-12
ATE445641T1 (de)	2009-10-15
CN101254300B (zh)	2013-05-08
US5990077A (en)	1999-11-23
CN1188485A (zh)	1998-07-22
ES2334864T5 (es)	2013-04-08
JP2010159259A (ja)	2010-07-22
CA2218225C (en)	2014-09-23
JPH11505521A (ja)	1999-05-21
WO1996032414A1 (en)	1996-10-17
CN100374461C (zh)	2008-03-12
DK0830377T3 (da)	2010-03-01

Publication	Publication Date	Title
CY2615B2 (en)	2012-01-25	Glucagon-like peptide-2 and its therapeutic use
EP2218734A3 (en)	2010-10-13	Glucagon-like peptide-2 analogs
ZA975866B (en)	1998-02-23	Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
MY128809A (en)	2007-02-28	Pharmaceutical formulation of omeprazole
IL130931A0 (en)	2001-01-28	Small molecules useful in the treatment of inflammatory disease
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE205086T1 (de)	2001-09-15	Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
NO962088L (no)	1996-05-22	Preparat for in vivo-produksjon av terapeutiske produkter
ATE338771T1 (de)	2006-09-15	Antagonisten des intestinotrophen glp-2 peptides
HUP9800467A3 (en)	1999-01-28	Use of hyaluronic acid for producing pharmaceutical compns. for the treatment of interstitial cystitis
ZA926241B (en)	1993-10-04	Dosage form for delivering drug in short-time period
GEP20074095B (en)	2007-04-25	Analogs of human insulin modified at position 29 of the b chain thereof
NO954996D0 (no)	1995-12-08	Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
MX9704030A (es)	1998-02-28	1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
FI964332A0 (fi)	1996-10-28	Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
WO1999022722A3 (en)	1999-08-05	Use of macrolides for the treatment of cancer and macular degeneration
ATE260117T1 (de)	2004-03-15	Pharmazeutische zusammensetzung zur behandlung von parkinsonkrankheit oder depression
BG105275A (en)	2001-11-30	Tan-1057 derivatives
EP0744176A3 (en)	2002-05-15	Methods for inhibiting bone loss
AU1898792A (en)	1994-01-04	Treatment or therapeutic booth for energetic, cosmetic and medical purposes
AU8020791A (en)	1992-02-06	Method and product for the treatment of gastric disease
DK0703781T3 (da)	2000-10-02	Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
ATE147988T1 (de)	1997-02-15	Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
ZA933086B (en)	1993-11-01	Novel method of treatment of Parkinson's disease
ID20165A (id)	1998-10-15	Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis